Cerus (NASDAQ:CERS) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Thursday.
A number of other equities analysts have also recently issued reports on CERS. Cowen set a $6.00 price objective on shares of Cerus and gave the company a “buy” rating in a research note on Thursday, October 5th. Robert W. Baird reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Cerus in a research note on Friday, December 1st. Zacks Investment Research raised shares of Cerus from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a research note on Wednesday, November 8th. BTIG Research reaffirmed a “neutral” rating on shares of Cerus in a research note on Friday, December 8th. Finally, BidaskClub cut shares of Cerus from a “hold” rating to a “sell” rating in a research note on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Cerus presently has an average rating of “Hold” and an average target price of $6.17.
Shares of Cerus (NASDAQ CERS) traded up $0.13 during trading on Thursday, hitting $3.72. 493,639 shares of the company were exchanged, compared to its average volume of 583,966. The company has a current ratio of 3.71, a quick ratio of 3.11 and a debt-to-equity ratio of 0.80. The firm has a market capitalization of $424.40, a price-to-earnings ratio of -6.31 and a beta of 1.93. Cerus has a fifty-two week low of $1.93 and a fifty-two week high of $4.70.
A number of hedge funds have recently made changes to their positions in CERS. Elk Creek Partners LLC boosted its stake in Cerus by 32.3% in the second quarter. Elk Creek Partners LLC now owns 5,739,285 shares of the biotechnology company’s stock valued at $14,406,000 after acquiring an additional 1,402,106 shares during the last quarter. Ark Investment Management LLC boosted its position in shares of Cerus by 126.5% during the second quarter. Ark Investment Management LLC now owns 1,680,925 shares of the biotechnology company’s stock worth $4,219,000 after purchasing an additional 938,647 shares in the last quarter. First Midwest Bank Trust Division boosted its position in shares of Cerus by 50.3% during the third quarter. First Midwest Bank Trust Division now owns 1,078,277 shares of the biotechnology company’s stock worth $2,944,000 after purchasing an additional 360,785 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Cerus by 3.9% during the second quarter. Vanguard Group Inc. now owns 4,892,503 shares of the biotechnology company’s stock worth $12,281,000 after purchasing an additional 184,076 shares in the last quarter. Finally, Premier Asset Management LLC bought a new position in shares of Cerus during the third quarter worth $348,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.
Cerus Company Profile
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.